Indoline PD-L1 Inhibitors for Tumor Tissue Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PD-L1 monoclonal antibody medicaments for treating tumors have limitations such as tissue penetration issues, high production costs, and unfavorable pharmacokinetic properties, necessitating the development of small molecule inhibitors with improved in vitro and in vivo activity.
Innovation Solution
Development of a new class of indoline compounds or their pharmaceutically acceptable salts, which act as small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway, offering better tissue distribution and pharmacokinetic properties, including faster half-life and broader tissue distribution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-L1 monoclonal antibody medicaments are used for treating tumors, then immune suppression can be blocked, but tissue penetration is poor and production costs are high
Solution Approach 1:
The patent transforms the macromolecular antibody structure into small molecule compounds with molecular weights typically between 200-1000 Da. This parameter change in molecular size fundamentally improves tissue penetration while maintaining PD-L1 inhibition capability through optimized chemical structures containing core scaffolds and specific functional groups that bind to PD-L1 binding sites.
2Reliability
If PD-L1 monoclonal antibody medicaments are used for treating tumors, then immune suppression can be blocked, but production costs are high
Solution Approach 1:
The patent employs small molecule compounds that can be synthesized through conventional organic chemistry methods using readily available starting materials and standard reagents. These small molecules are inherently cheaper to produce than macromolecular antibodies, which require complex cell culture and purification processes. The simplified synthetic routes and use of common chemical building blocks significantly reduce manufacturing costs.
3Reliability
If PD-L1 monoclonal antibody medicaments are used for treating tumors, then immune suppression can be blocked, but pharmacokinetic properties are unfavorable
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by designing small molecule compounds with appropriate lipophilicity, molecular weight, and functional group composition. These structural parameters are tuned to achieve favorable absorption, distribution, metabolism, and excretion (ADME) properties. The small molecule format inherently provides different pharmacokinetic profiles compared to antibodies, including potential for oral administration and adjusted half-life through metabolic stability optimization.
4Weight of moving object
If small molecule PD-L1 inhibitors are developed, then tissue penetration and pharmacokinetic properties are improved, but in vitro and in vivo activity needs further enhancement
Solution Approach 1:
The patent employs composite molecular structures combining core scaffolds with multiple functional groups that collectively enhance both tissue penetration and biological activity. The molecular design integrates hydrophobic regions for membrane penetration with hydrophilic regions for solubility, along with specific binding moieties for PD-L1 interaction. This composite structural approach allows simultaneous optimization of pharmacokinetic properties and pharmacodynamic efficacy.
Data Source
AI summary
An indoline compound. Specifically disclosed is an application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in the preparation of drugs for treating related diseases.